et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–93., , ,
et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism The Worcester DVT Study. Arch Intern Med 1991; 151: 933–8., , ,
Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther 2007; 29: 2395–405., , , , .
et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–9., , ,
et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients prophylaxis in medical patients with enoxaparin Study Group. N Engl J Med 1999; 341: 793–800., , ,
et al. Prevention of venous thromboembolism: american college of chest physicians evidence-based clinical practice guidelines. (8th Edition)Chest 2008; 6(Suppl): 381S–453S., , ,
et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 2007; 132: 936–45., , ,
et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524–8., , ,
et al. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008; 100: 259–62., , ,
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci 2008; 53: 3012–7., , , , .
et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96–101., , ,
Deep vein thrombosis and pulmonary embolism in hospitalized patients with cirrhosis: a nationwide analysis. Dig Dis Sci 2011; 56: 2152–9., , , .
et al. The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients. Thromb J 2011; 9: 1., , ,
Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8: 800–5., .
Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 2010; 137: 1145–9., , , , .
The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–56., .
et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53: 362–71., , ,
Hypercoagulation in liver disease. Clin Liver Dis 2009; 13: 109–16..
et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137: 2105–11., , ,
et al. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132–6., , ,
Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388–93..
Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB (Oxford) 2009; 11: 459–64., , .
et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691–7., , ,
et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44 : 448–51., , ,
et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776–83., , ,
et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919–27., , ,
et al. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients with Advanced Cirrhosis. Gastroenterology 2012; 143: 1253–60., , ,
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 6(Suppl): 340S–80S., , , .
et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69–79., , ,
Subcommittee on Control of Anticoagulation of the S Standardization Committee of the International Society on T Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and haemostasis: JTH 2005; 3: 692–4., .
Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 32: 1465–76., , , .
Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med 2009; 4: 161–2., , , .
et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75–82., , ,
et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol 2010; 16: 2146–50., , ,
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710–5., , .